Furthermore, based on the corresponding Colorectal Cancer Subtype Consortium analysis of a comprehensive CRC dataset, the authors showed that male KRAS*CRC patients had lower survival rates than female KRAS*CRC patients. This evidence concerns the gene KRAS and colorectal carcinoma.